CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.
- Author:
Hyung Bae PARK
1
;
Ji Eun LEE
;
Yu Mi OH
;
Sang Jin LEE
;
Hyeon Seok EOM
;
Kyungho CHOI
Author Information
- Publication Type:Original Article
- MeSH: Chimera*; Graft vs Host Disease; Hematologic Neoplasms*; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-10; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes*; Mesenchymal Stromal Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; T-Lymphocytes*; Tissue Donors*
- From:Experimental & Molecular Medicine 2017;49(7):e360-
- CountryRepublic of Korea
- Language:English
- Abstract: Donor lymphocyte infusion (DLI) followed by hematopoietic stem cell transplantation has served as an effective prevention/treatment modality against the relapse of some hematologic tumors, such as chronic myeloid leukemia (CML). However, the therapeutic efficacies of DLI for other types of leukemia, including acute lymphocytic leukemia (ALL), have been limited thus far. Therefore, we examined whether increasing the reactivity of donor T cells by gene modification could enhance the therapeutic efficacy of DLI in a murine model of ALL. When a CTLA4-CD28 chimera gene (CTC28) in which the intracellular signaling domain of CTLA4 was replaced with the CD28 signaling domain was introduced into CD4 and CD8 T cells in DLI, the graft-versus-tumor (GVT) effect was significantly increased. This effect was correlated with an increased expansion of donor CD8 T cells in vivo, and the depletion of CD8 T cells abolished this effect. The CD8 T cell expansion and the enhanced GVT effect were dependent on the transduction of both CD4 and CD8 T cells with CTC28, which emphasizes the role of dual modification in this therapeutic effect. The CTC28-transduced T cells that expanded in vivo also exhibited enhanced functionality. Although the potentiation of the GVT effect mediated by the CTC28 gene modification of T cells was accompanied by an increase of graft-versus-host disease (GVHD), the GVHD was not lethal and was mitigated by treatment with IL-10 gene-modified third-party mesenchymal stem cells. Thus, the combined genetic modification of CD4 and CD8 donor T cells with CTC28 could be a promising strategy for enhancing the therapeutic efficacy of DLI.
